Skip to main content
Premium Trial:

Request an Annual Quote

Biocept: Samuel Riccitelli

Biocept has appointed Samuel Riccitelli to its board of directors, effective immediately, and ahead of the planned retirement of Bruce Huebner, who will leave the board on Nov. 30, 2020Riccitelli boasts 35 years of experience in the molecular diagnostics industry, having served in executive-level positions and on the boards of multiple publicly traded companies. At Biocept, he will initially serve on the audit committee and the science and technology committee.

Riccitelli currently serves as an independent consultant to healthcare companies and is a director of OrthoPediatrics, a company focused on the orthopedic implant needs of children. Prior to that he was CEO of Pathnostics, a molecular diagnostics company focused on improving antibiotic stewardship. He also served as chairman of Precipio; president, CEO, and director of Signal Genetics; and executive VP and chief operating officer of Genoptix. Riccitelli received a BA from Washington and Jefferson College and an MS in engineering from The University of Texas.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.